Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer

February 16th 2023

A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.

Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial

February 16th 2023

Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.

Dr. Costa on the Implications of the KEYNOTE-522 Trial in TNBC

February 15th 2023

Ricardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.

RxPONDER Analysis Reveals Racial Disparities in HR+/HER2– Breast Cancer

February 15th 2023

Yara Abdou, MD, discusses the racial and clinical analysis of the RxPONDER trial, the need to further investigate the factors that create racial disparities in breast cancer, and the importance of enrolling minority populations onto clinical trials.

Elacestrant Secures a Place for ER+, HER2–, ESR1-Mutated Advanced/Metastatic Breast Cancer

February 15th 2023

François-Clément Bidard, MD, PhD, discusses how elacestrant fits into the treatment paradigm for postmenopausal patients with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

NCCN Adds MammaPrint Gene Expression Assay to Breast Cancer Guidelines

February 14th 2023

The National Comprehensive Cancer Network breast cancer guidelines issued February 7, 2003, added the MammaPrint UltraLow Risk gene expression assay to its list of recommended assays for consideration of adjuvant systemic therapy.

2023 Cancer Trends Highlight Opportunities to Close Gaps in Care in Community Practice

February 14th 2023

A renewed focus on dismantling the barriers and closing gaps in care will aid in the mission to drive down the rate of cancer mortality and incidence across disease states.

Adjuvant Everolimus Plus Standard ET Does Not Significantly Improve iDFS or OS in HR+ Breast Cancer

February 14th 2023

Mariana Chavez-MacGregor, MD, MSC, discussed key efficacy and safety data from the SWOG 1207 trial of adjuvant everolimus in postmenopausal patients with high-risk, hormone receptor–positive breast cancer.

Invasive Lobular Carcinoma Comes Into Sharper Focus

February 13th 2023

Research groups in the United States and Europe are seeking to build the knowledge base about invasive lobular carcinoma in hopes that therapy can be tailored for patients with this diagnosis.

Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

February 13th 2023

Joyce O’Shaughnessy, MD, starts a conversation on which patients with HER2+ early breast cancer are the best candidates for extended adjuvant neratinib therapy.

The Role of Capivasertib in ER+/HER- mBC

February 13th 2023

Komal Jhaveri, MD, FACP, discusses the role of capivasertib in ER-positive HER2-negative mBC and the design and outcomes of the CAPItello 291 trial.

Closing Remarks on Treating Patients with HR+ Breast Cancer

February 13th 2023

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.

Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

February 13th 2023

A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.

Dr. Wander on the Role of NF1 Mutations on CDK4/6 Resistance in Breast Cancer

February 10th 2023

Seth Wander, MD, PhD, discusses the investigation of resistance to CDK4/6 inhibitors and the role of NF1 mutations in breast cancer.

Dr. Neven on the Relationship of Cell Cycle Genes and Outcomes in HR+/HER2– Breast Cancer

February 10th 2023

Patrick Neven, MD, discusses the association between cell cycle–related genes and outcomes for patients with hormone receptor–positive/HER2-negative advanced breast cancer treated on the phase 3 MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials.

How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer

February 9th 2023

A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.

Best Practices for Molecular Testing in Early-Stage Breast Cancer

February 9th 2023

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

Trastuzumab Deruxtecan in the Neoadjuvant Setting

February 8th 2023

Closing thoughts on the TALENT study concerning the use of neoadjuvant trastuzumab deruxtecan in patients with HER2-low, HR+ early-stage breast cancer.

Dr. Falkson on the Use of Sacituzumab Govitecan in HR+/HER2- Breast Cancer

February 7th 2023

Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.

Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

February 7th 2023

The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.